FDA warned Orean Personal Care Ltd. that repeat manufacturing failures make its OTC drugs adulterated.
What happened
FDA inspected the Cleckheaton facility from March 11 to 15, 2024, and reviewed the company's April 4, 2024 response to the Form FDA 483, a list of inspection observations. It found significant violations of current good manufacturing practice (CGMP): inadequate testing of incoming components, inadequate process and cleaning validation, and insufficient quality unit oversight. FDA said several findings were repeats from a 2017 inspection and that the company had not fulfilled its 2017 commitments.
What FDA found
The company did not test each incoming component lot, including its active pharmaceutical ingredient, for identity and other specifications, and relied on supplier certificates of analysis without establishing their reliability.
21 CFR 211.84(d)(1) and 211.84(d)(2)The company did not adequately validate its manufacturing processes; it adjusted component amounts after out-of-specification viscosity results and did not place new bulk batches that involved remaining portions of previous bulk batches on stability.
21 CFR 211.100(a)The company had not validated cleaning of non-dedicated equipment used for multiple products, risking cross-contamination.
21 CFR 211.67(b)The quality control unit failed to ensure adequate investigations of non-conformances.
21 CFR 211.22 and 211.192The quality control unit failed to ensure adequate document control and retention, including missing or incomplete batch records and testing records.
21 CFR 211.22 and 211.188The quality control unit failed to ensure an adequate ongoing stability program and annual product quality reviews.
21 CFR 211.22, 211.166(a), and 211.180(e)
What FDA wants
FDA tells Orean to correct the violations promptly and respond in writing within 15 working days with what it has done and plans to prevent recurrence. If it cannot complete corrective actions in that time, it must state why and provide a completion schedule; FDA also recommends a qualified CGMP consultant.
Who should pay attention
- brands that buy OTC drug products made at this facility
- companies that purchase or distribute its finished drug products
- quality teams that rely on supplier certificates of analysis
This is a summary. Read the original letter on fda.gov.